Ceo spotlight: acurx pharmaceuticals ceo confident his phase 2b ibezapolstat drug candidate can earn front-line designation to treat c. difficile

Acurx pharmaceuticals ceo david luci tells soulstring media group why he thinks his company and lead drug candidate, ibezapolstat, can be a front-line treatment against c. difficilenew york, new york--(newsfile corp. - february 7, 2023) - soulstring media group, llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth interview with acurx pharmaceuticals (nasdaq: acxp) president and ceo, mr. david luci. the interview discusses acxp's ongoing phase 2b trial utilizing ibezapolstat to treat c.
ACXP Ratings Summary
ACXP Quant Ranking